Find clinical trials for Triple Negative Breast Cancer in Washington, DC
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Triple Negative Breast Cancer trials near Washington, DC, USA:
The goal of this clinical trial is to evaluate the safety and efficacy of 3 different dose levels of CLR 125 in patients with advanced triple...
Phase 1
Glen Burnie, Maryland, United States and 3 other locations
of durvalumab in combination with novel oncology therapies with or without paclitaxel and durvalumab + paclitaxel for first-line metastatic triple...
Phase 1, Phase 2
Columbia, Maryland, United States and 31 other locations
selective inhibition of phosphoinositide-3-kinase (PI3K)-gamma, in combinations with Tecentriq and Abraxane (nab-paclitaxel) in front-line triple...
Phase 2
Baltimore, Maryland, United States and 23 other locations
doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC). Usually, after neoadjuvant therapy and surgery for triple ne ...
Phase 3
Silver Spring, Maryland, United States and 216 other locations
avelumab with sacituzumab govitecan works in treating patients with triple negative breast cancer that is stage I...
Phase 2
Washington D.C., District of Columbia, United States and 11 other locations
and capecitabine) for the treatment of first-line metastatic triple-negative breast cancer (TNBC) or estrogen rec...
Phase 2, Phase 3
Baltimore, Maryland, United States and 294 other locations
or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after su...
Phase 3
Washington D.C., District of Columbia, United States and 372 other locations
This study is one single group of participants with non-small cell lung cancer (NSCLC) who have not been cured by other treatments. It is th...
Phase 1
Washington D.C., District of Columbia, United States and 17 other locations
previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do no...
Phase 3
Baltimore, Maryland, United States and 374 other locations
cell line. The antibody AG01 binds to human PGRN/GP88, expressed on cancer cells.This study will have a dose escalation portion (1A) to eval...
Phase 1
Baltimore, Maryland, United States
Clinical trials
Research sites
Resources
Legal